Aimmune price target raised to $50 from $45 at Roth Capital » 09:0301/2301/23/20
Roth Capital analyst…
Roth Capital analyst Zegbeh Jallah raised her price target for Aimmune to $50 from $45 as the analyst remains bullish on Palforzia's launch outlook. Jallah notes that FDA's decision on Palforizia is still expected by the end of January, and EMA's approval of Palforzia is expected during the second half of 2020. The analyst has a Buy rating on the shares.
|Over a week ago|
Aimmune still has most efficacious peanut allergy treatment, says Cantor » 07:1701/1001/10/20
After DBV Technologies…
After DBV Technologies (DBVT) reported topline results for the open label extension of the Phase PEPITES trial, Cantor Fitzgerald analyst Charles Duncan says Aimmune Therapeutics (AIMT) still has the only drug to successfully complete Phase 3 studies and the most efficacious therapeutic for peanut allergy in development. Further, the analyst is "dubious" of DBV's use of "eliciting dose" versus "tolerated dose" as the efficacy measure because he believes that the former may "over-sell" the level of desensitization measured by the dose at which patients respond because investigators can coach beyond symptoms and the more conservative measure would be the dose prior. In a research note titled "Apples Vs Oranges: PALFORZIA Clinical Benefit is Clear, Other Candidate's Not So Much," Duncan keeps an Overweight rating on Aimmune with a $55 price target.
Aimmune Therapeutics call volume above normal and directionally bullish » 12:4512/3012/30/19
Bullish option flow…
Bullish option flow detected in Aimmune Therapeutics with 1,826 calls trading, 1.2x expected, and implied vol increasing almost 8 points to 85.46%. Feb-20 35 calls and Feb-20 40 calls are the most active options, with total volume in those strikes near 710 contracts. The Put/Call Ratio is 0.06. Earnings are expected on February 27th.
|Over a month ago|
Aimmune Therapeutics call volume above normal and directionally bullish » 13:0512/1912/19/19
Bullish option flow…
Bullish option flow detected in Aimmune Therapeutics with 1,620 calls trading, 1.2x expected, and implied vol increasing over 2 points to 70.03%. Dec-19 30 calls and Jan-20 30 calls are the most active options, with total volume in those strikes near 1,100 contracts. The Put/Call Ratio is 0.06. Earnings are expected on February 27th.
DBV safety profile a competitive advantage, says H.C. Wainwright » 07:1712/1912/19/19
H.C. Wainwright analyst…
H.C. Wainwright analyst Andrew Fein views the safety profile of DBV Technologies' (DBVT) Viaskin safety profile as a competitive advantage. After surveying 100 allergists, the analyst notes that the doctors expected their treated peanut allergy patients to grow by approximately 59% from the current year to five years from now. A key takeaway was that allergists identified safety and efficacy as their top concerns in treating peanut allergy patients, Fein tells investors in a research note. He believes this highlights a fundamental distinction between DBV's Viaskin, which he says offers efficacy with a superior safety profile, and Aimmune's (AIMT) Palforzia, which he says offers high reported efficacy with greater allergic reaction risk. Fein continues to believe these priorities can indicate relevance for both drugs, while emphasizing safety. He reiterates a Buy rating on DBV Technologies with a $25 price target. The analyst this morning also imitated Aimmune with a Neutral rating.
Aimmune initiated with a Neutral at H.C. Wainwright » 07:1012/1912/19/19
H.C. Wainwright analyst…
H.C. Wainwright analyst Andrew Fein initiated coverage of Aimmune with a Neutral rating and $33 price target. The analyst believes Palforzia can be first to market without currently approved treatment alternatives for peanut allergy. However, his concerns center around safety. Although adverse events were shown to decrease over time, prospective physicians and parents with safety concerns considering Palforzia could be "aversive" to allergic reactions, Fein tells investors in a research note.
Aimmune Therapeutics call volume above normal and directionally bullish » 14:2512/1812/18/19
Bullish option flow…
Bullish option flow detected in Aimmune Therapeutics with 1,633 calls trading, 1.0x expected, and implied vol increasing almost 3 points to 68.32%. Dec-19 30 calls and Jan-20 40 calls are the most active options, with total volume in those strikes near 1,000 contracts. The Put/Call Ratio is 0.03. Earnings are expected on February 27th.
Piper a buyer of Aimmune, Global Blood, Horizon into 2020 launches » 05:3312/1712/17/19
AIMT, GBT, HZNP
Analysts at Piper Jaffray…
Analysts at Piper Jaffray are buyers of Aimmune Therapeutics (AIMT), Global Blood Therapeutics (GBT) and Horizon Pharma (HZNP) into expected 2020 launches. Over the last five years, more launches have underperformed than outperformed, and the stock reactions have been largely proportionate to the level of under/over performance, the analysts tell investors in a research note. However, they point out that under the "somewhat rare circumstances" where performance has beaten expectations meaningfully, the stock reactions "can pay off handsomely." As such, Piper believes these three stocks can beat the "well entrenched biopharma default thesis to 'short the launch.'"
DBV Technologies initiated with a Buy at Citi » 06:5912/1612/16/19
Citi analyst Joel Beatty…
Citi analyst Joel Beatty initiated coverage of DBV Technologies (DBVT) with a Buy rating and $14 price target. The analyst sees a 60% probability of approval for DBV's lead agent Viaskin Peanut, a once-daily patch for peanut-allergic children. The shares have $9 upside if approved and downside to under $1 if not approved, Beatty tells investors in a research note. The analyst believes Viaskin Peanut's treatment effect has been validated by the statistically significant benefits reported from the Phase 3 primary and secondary endpoints. Further, recent publications suggest that the magnitude of benefit observed in the majority of subjects treated by Viaskin Peanut is clinically meaningful, adds the analyst. Beatty expects Viaskin Peanut to achieve a "slight majority" market share over Aimmune's (AIMT) oral competitor Palforzia and peanut sales reaching $900M-plus if approved.
Credit Suisse downgrades Aimmune with peanut allergy approval widely expected » 07:2212/1312/13/19
Credit Suisse analyst…
Credit Suisse analyst Evan Seigerman downgraded Aimmune Therapeutics to Neutral from Outperform with an unchanged price target of $30. The stock closed Thursday up 80c to $31.59. Approval of the company's peanut allergy treatment is now widely expected by investors, given the positive FDA advisory committee meeting in September, Seigerman tells investors in a research note. However, once approved, Palforzia could see commercial challenges given the new modality and required infrastructure, contends the analyst. He's "not negative" on Aimmune shares, he just believes much of the near-term upside has already been realized.